CASTLE BIOSCIENCES INC CSTL
Castle Biosciences is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett's esophagus ("BE"), atopic dermatitis ("AD"), uveal melanoma ("UM").
Since our inception in 2008, it has been our vision to transform disease management by keeping people first: patients, clinicians, employees and investors. This foundational strategy remains the guidepost for the direction of our company and the basis of long-term value creation.
Our tests are designed to deliver personalized information to help better inform clinical care decisions. For our core tissue-based tests, we use multi-analyte assays with algorithmic analysis ("MAAA") to characterize an individual patient's biology and generate clinically actionable information. Depending on the specific test, this information may be used to provide information to help guide treatment and patient management decisions including potential responsiveness to therapy and to assist in the diagnosis of a disease.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $344.2M | $332.1M | $219.8M | $137.0M | $94.1M | $62.6M | $51.9M | $22.8M | — |
| Cost of revenue | $71.0M | $60.2M | $45.0M | $32.0M | $15.8M | $9.7M | $7.3M | $5.3M | — |
| Gross profit | $273.2M | $271.9M | $174.8M | $105.0M | $78.3M | $53.0M | $44.6M | $17.5M | — |
| R&D | $51.9M | $52.0M | $53.6M | $44.9M | $29.6M | $13.3M | $7.4M | $4.9M | — |
| SG&A | $229.3M | $200.0M | $180.2M | $143.0M | $86.7M | $48.1M | $29.8M | $16.5M | — |
| Total operating expenses | — | — | — | — | — | — | $37.2M | $21.3M | — |
| Operating income | -$42.8M | $8.7M | -$68.0M | -$72.9M | -$40.1M | -$6.5M | $7.3M | -$3.8M | — |
| Interest expense | $86.0K | $577.0K | $11.0K | $17.0K | $1.0K | $2.6M | $4.6M | $2.3M | — |
| Pre-tax income | -$18.8M | $21.6M | -$57.4M | -$65.4M | -$22.6M | -$10.2M | $5.3M | -$6.4M | — |
| Income tax | $5.4M | $3.3M | $101.0K | $1.8M | $8.7M | $84.0K | $72.0K | $9.0K | — |
| Net income | -$24.2M | $18.2M | -$57.5M | -$67.1M | -$31.3M | -$10.3M | $5.3M | -$6.4M | — |
| EPS, basic | -0.83 | 0.66 | -2.14 | -2.58 | -1.24 | -0.54 | 0.35 | -5.33 | — |
| EPS, diluted | -0.83 | 0.62 | -2.14 | -2.58 | -1.24 | -0.54 | -0.21 | -5.33 | — |
| Shares, diluted (wtd. avg.) | $29.0M | $29.3M | $26.8M | $26.1M | $25.1M | $18.9M | $8.7M | $1.9M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $116.7M | $119.7M | $98.8M | $122.9M | $329.6M | $409.9M | $98.8M | $4.5M | $1.2M |
| Short-term investments | $171.6M | $169.9M | $144.3M | $135.7M | $0 | — | — | — | — |
| Receivables | $43.4M | $51.2M | $38.3M | $23.5M | $17.3M | $12.8M | $14.6M | $12.1M | — |
| Inventory | $10.3M | $8.1M | $7.9M | $4.0M | $2.0M | $2.2M | $1.2M | $882.0K | — |
| Total current assets | $361.1M | $360.2M | $295.6M | $292.3M | $353.7M | $429.6M | $116.7M | $18.1M | — |
| Property, plant and equipment | — | — | — | $14.3M | $9.5M | $7.1M | $2.1M | $1.5M | — |
| Goodwill | $10.7M | $10.7M | $10.7M | $10.7M | $0 | — | — | — | — |
| Other intangibles | $88.9M | $95.5M | $106.6M | $115.7M | $88.9M | $0 | $0 | $4.0K | — |
| Total assets | $578.6M | $531.2M | $453.3M | $447.3M | $462.6M | $439.3M | $119.7M | $22.4M | — |
| Accounts payable | $18.7M | $6.9M | $10.3M | $4.7M | $2.5M | $2.1M | $1.9M | $1.5M | — |
| Short-term debt | $417.0K | $278.0K | $0 | — | — | $0 | $5.8M | $0 | — |
| Total current liabilities | $68.7M | $49.4M | $47.7M | $36.1M | $24.9M | $20.9M | $15.3M | $6.7M | — |
| Long-term debt | $9.6M | $9.7M | $0 | — | — | $0 | $19.3M | $24.5M | — |
| Total liabilities | $107.7M | $75.4M | $62.1M | $48.2M | $50.8M | $23.6M | $34.6M | $32.5M | — |
| Retained earnings | -$224.3M | -$200.1M | -$218.4M | -$160.9M | -$93.8M | -$62.5M | -$52.2M | -$57.5M | — |
| Total equity | $470.9M | $455.8M | $391.3M | $399.1M | $411.7M | $415.7M | $85.1M | -$56.6M | -$50.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $64.3M | $64.9M | -$5.6M | -$41.7M | -$19.0M | $9.9M | $7.0M | -$12.3M | — |
| Depreciation and amortisation | $40.8M | $16.0M | $12.3M | $10.5M | $3.4M | $472.0K | $354.0K | $287.0K | — |
| Stock-based compensation | $45.9M | $50.3M | $51.2M | $36.3M | $21.7M | $8.3M | $1.2M | $294.0K | — |
| Capital expenditure | $36.0M | $28.3M | $13.6M | $5.6M | $3.5M | $4.8M | $937.0K | $277.0K | — |
| Investing cash flow | -$60.4M | -$50.1M | -$16.2M | -$166.5M | -$66.7M | -$4.7M | -$937.0K | -$277.0K | — |
| Financing cash flow | -$7.0M | $6.1M | -$2.3M | $1.5M | $5.4M | $305.9M | $88.3M | $15.8M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-024166.
Others in SIC 8071
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| NTRA | Natera, Inc. | $47.31B | — | 35.9% |
| LH | LABCORP HOLDINGS INC. | $26.51B | 31.3x | 7.2% |
| DGX | QUEST DIAGNOSTICS INC | $26.17B | 27.1x | 11.8% |
| GH | Guardant Health, Inc. | $21.66B | — | 32.9% |
| CAI | Caris Life Sciences, Inc. | $7.08B | — | 97.0% |
| RDNT | RadNet, Inc. | $5.80B | — | 11.5% |
| CELC | Celcuity Inc. | $4.68B | — | — |
| BLLN | BillionToOne, Inc. | $4.61B | 709.9x | 100.0% |